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Results
Transgene expression was localized to adventitia. All decoy receptors reduced the size of vasavasorum at 14d, AdsVEGFR2 animals also had reduced density of adventitial vasa-vasorum, whereas AdsVEGFR3 increased the density of vasa-vasorum. At d42, AdsVEGFR1 and AdsVEGFR2 reduced ISR (15.7±6.9% stenosis, P<0.01 and 16.5±2.7%, P<0.05, respectively) vs. controls (28.3±7.6%). Moreover, AdsVEGFR-3 treatment led to a non-significant trend in the reduction of adventitial lymphatics at all time points and these animals had significantly more advanced neointimal atherosclerosis at 14d and 42d vs. control animals.
Conclusions
Targeting adventitial neovascularization using sVEGFR1 and sVEGFR2 is a novel strategy to reduce ISR. The therapeutic effects dissipate at late follow up following short expression profile of adenoviral vectors. However, inhibition of VEGFR3 signaling accelerates neoatherosclerosis.
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INTRODUCTION
Percutaneous revascularization techniques have revolutionized the treatment of patients suffering from coronary artery disease [1, 2] . The introduction of stents prevented elastic recoil and negative remodeling of coronary arteries after angioplasty [3] , a key limitation of catheter based treatments until that time. Atherosclerotic disease and mechanical injury caused by the stent itself, however, commonly leads to a new narrowing [4] . This in-stent restenosis (ISR) has been reduced by the discovery of drug eluting stents (DES) [5] . The strong cytotoxic drugs used in DES commonly inhibit ISR, but also delay recovery of the protective endothelial layer leading to prolonged risk of stent thrombosis (ST) and reliance on antithrombotic medication [6] .
Plaque angiogenesis has been suggested as one of the major factors in the progression of atherosclerotic lesions [7] and may be driven by hypoxia and energy depletion in macrophage-rich lesion core [8, 9] . Intimal and medial cells activate angiogenesis by secretion of several growth factors including Vascular Endothelial Growth Factor A (VEGF-A) [10, 11] . This is aggravated by growth factor and cytokine secretion from inflammatory cells, also found in abundance in atherosclerotic lesions. VEGF-A signaling is mediated through VEGFR1 and VEGFR2 with VEGFR1 acting as a decoy receptor as well as transducing weak signals for endothelial growth.
VEGFR2 is a key mediator of endothelial cell survival and angiogenesis [12] . VEGF-A signaling leads to the growth of new vasa vasorum from the adventitial layer of the artery. Neoangiogenic capillaries are often poorly organized and leaky, which can lead to small hemorrhages in the growing lesion and to rupture prone, vulnerable plaques [9] [10] [11] . While abundant vasa vasorum have been linked to the growth of atherosclerotic lesions [11] , and although descriptive studies have reported a correlation between the vasa vasorum density and the percent luminal stenosis after balloon injury [13] , the role of plaque angiogenesis in the formation of ISR has remained elusive.
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Similarly the role of lymphangiogenesis and VEGFR3 signaling, the main driver for the growth of lymphatic vessels, is unclear in the ISR formation. In vivo VEGFR3 activation by VEGF-C and VEGF-D triggers the growth of lymphatic vessels. In experimental setting reduced activity of VEGF-C has been shown to elevate cholesterol levels and accelerate atherogenesis [14] . However, the effects of lymphangiogenesis and lymphatic structures on ISR are unknown.
We studied the effects of anti-angiogenic therapy on the development of ISR in a clinically relevant triple injury model [15] . Adenoviruses encoding soluble decoy receptors (sVEGFR) 1, 2 and 3 or control LacZ were infused intramurally into the vascular wall at the time of stenting. Analyses of the control animals at 6d demonstrated the marker protein expression in the outer layers of media and in the adventitia. sVEGFRs expressed by cells in the abluminal vessel layers act as secreted decoy receptors and bind to VEGFs, thus limiting their biological activity and reducing angiogenesis and lymphangiogenesis [16] . We hypothesized that adventitial sVEGFR overexpression would lead to attenuated angiogenesis or vasa vasorum growth and ultimately have an effect on in-stent restenosis.
METHODS
Adenoviruses
Replication-deficient E1-partially E3-deleted clinical GMP-grade adenoviruses encoding nucleartargeted β-galactosidase (LacZ) or soluble VEGF receptors 1, 2 and 3 were produced and tested to be free of contaminants [17] . The same adenoviral constructs have been studied previously and shown to produce transgene products and be biologically active in-vivo [18] . anesthesia [15] . Denudation was performed between the level of the renal arteries and aortic bifurcation. Six weeks after the denudation the rabbits were anesthetized again and a 6F introducer sheath (Avanti+, Cordis) was placed into the right carotid artery exposed through a mid-line incision. A guiding catheter (Vista Brite Tip, Cordis) and a guide wire (Stabilizer, Cordis) were advanced to the descending aorta under fluoroscopic guidance (GE Innova 3100IQ, GE Healthcare).
Angiography was performed, the guiding catheter removed and Infiltrator® (IVT, Boston At the end of the follow up, the animals were sacrificed with a large i.v. bolus of saturated MgSO 4 under general anesthesia and the vasculature was perfused with PBS. The stented segment of the aorta was fixed with paraformaldehyde and mounted in methacrylate and processed further for histopathological analyses [15] . Tissue samples from the heart, lung, liver, spleen, kidney and skeletal muscle were harvested for general histology and biodistribution analyses and were embedded into paraffin blocks after tissue fixation and dehydration. Segments of aorta from the edges of the stent were processed through paraffin histology and stained for β-galactosidase from d6 animals.
Histology
Stents were segmentally cut into ≤7 µm serial sections and stained with hematoxylin and eosin as well as Van Gieson stain for elastin [15] . Adventitial vessels were quantified from CD31 stained sections. CD31 positive vessels were counted and their cross-sectional area measured from the adventitia [15, 19] . The number of vessels is expressed as number of vessels per mm 2 of tissue. Similar measurements were carried out for lymphatic vessels from LYVE-1 stained samples [14] . Endothelialization was determined from CD31 stained sections as the percentage of luminal circumference covered by CD31 positive cells.
Proliferating cell nuclei were identified in the neointima from Ki-67 staining. Data is expressed as the number of cells per mm 2 of neointima. Areas identified from RAM-11 staining containing macrophages were outlined and data is shown as macrophage density in the neointima [20] .
The stented aortic segments were further characterized by determining the injury score [21] and evaluating the severity and type of the atherosclerotic changes. The severity of atherosclerotic changes in neointima was assessed and a grade between I-VI [22, 23] 
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Statistical analysis
All results were analyzed for statistical significance using one-way ANOVA with Dunnet's post hoc test with GraphPad Prism 6 software (GraphPad Software, La Jolla, CA, USA). P values less than 0.05 were considered significant. All data are expressed as mean ± SD.
RESULTS
Gene transfer
Marker gene expression was confirmed in LacZ treated aortas at six days after the gene transfer. Table 1 ). There were no significant differences at later time points of 42 and 90 days ( Figure 3) .
A C C E P T E D M A N U S C R I P T Luminal endothelialization
No differences were observed in the rate of luminal re-endothelialization. The endothelial layer had recovered moderately in all groups by two weeks. None of the groups showed complete endothelialization even at the three-month follow-up (Table 1) .
In-stent restenosis
The ISR calculated as the percentage narrowing of the stented lumen was significantly decreased in the AdsVEGFR1 and AdsVEGFR2 treated groups compared to controls 42d after stenting (15.7±6.9, 16.5±2.7 and 28.3±7.6 percent restenosis for AdsVEGFR1, AdsVEGFR2 and AdLacZ, respectively; P<0.01 for AdsVEGFR1 and P<0.05 for AdsVEGFR2) (Figure 4 ). No significant differences were observed at other time points or treatment with AdsVEGFR3 (Table 1) .
Macrophage infiltration and lesion characteristics
Moderate macrophage infiltration was seen in all groups. The macrophage density was generally greater in areas surrounding the stent struts ( Figure 5 ). No differences were observed between the groups ( Table 1 ).
The in-stent neointimal lesions displayed more advanced atherosclerotic changes at d14 in AdsVEGFR3 treated arteries compared to control with a score of 3.7±0.6 vs. 2.4±0.8 in AdLacZ, P<0.05 ( 2.8±0.8 and 2.3±0.5 for AdsVEGFR1 and AdsVEGFR2, respectively, P=NS) )( Figure 5 ).
The same was also seen at d42 with AdsVEGFR3 treated rabbits with a score of 4.0±1.0 vs. 2.5±1.0 in AdLacZ, P<0.05 ( 2.7±0.8 and 2.6±0.5 for AdsVEGFR1 and AdsVEGFR2, respectively, P=NS).
There were no significant differences at d90.
Adventitial lymphatic vessels
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Treatment with sVEGFR3 resulted in a trend towards reduced number of LYVE-1 positive lymphatic vessels in the adventitia at all time-points although the difference was not statistically significant ( Figure 6 ). Gene transfers with other sVEGFRs did not influence the growth of lymphatic vessels (Table 1) .
Neointimal proliferation
No statistically significant differences were observed in the number of proliferating cells in the neointima in any of the time points. At d14 proliferation counts were 62.2±27. 
Blood chemistry and safety analyses
No signs of toxicity or side effects were found based on clinical chemistry (Table 2 ) and histopathological analysis of the major organs ( Supplementary Figures 1-5 ). There were no differences between the groups in local inflammatory responses, neointimal proliferation or injury scores (Table 1) .
DISCUSSION
The role of vasa vasorum in the formation of primary atherosclerotic lesions has previously been suggested [11] . In this study we show that by blocking angiogenic signaling using adventitial expression of decoy receptors for VEGFR1 or VEGFR2 reduces the number and size of adventitial vasa vasorum, and leads to reduction of ISR. Conversely, periadventitial targeting of pro lymphangiogenic VEGFR3 activation with decoy inhibitors resulted in a more adverse in-stent
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neointimal atherosclerotic phenotype. We utilized an atherosclerotic model in which a lesion is created in a hypercholesterolemic animal with additional balloon injury prior to the stenting procedure to mimic the clinical setting of coronary stenting. Time-points were selected to address the acute changes after peak transgene expression at d14, the subacute changes in restenosis formation at d42 and chronic lesion development at d90. Use of the intermediate d42 time-point is well documented in prior literature [23, 24] . Limitations of the study are the lack of a solvent group with injections lacking viral particles and a stent group without drug delivery catheter intervention.
Treatment with AdsVEGFR1 and AdsVEGFR2 resulted in an attenuated adventitial angiogenic response two weeks after the treatment, following the peak transgene expression of adenovirus vector system [26] . Possibly due to the limited duration of expression of adenoviruses, the effect on the vasa vasorum size and density was lost at the later time points. The main angiogenic signaling occurs via the VEGFR2 pathway whereas the VEGFR1 acts partly as a decoy receptor in the physiological setting [12] . In this study, treatment with AdsVEGFR2 resulted in both fewer and smaller adventitial vessels while AdsVEGFR1 treatment only affected the size of vasa-vasorum suggesting that targeting VEGFR2 pathway might be the most potent approach for the inhibition of the growth of vasa vasorum. However, both AdsVEGFR1 and AdsVEGFR2 treatments resulted in similar reductions in ISR at six weeks follow up.
Following the impaired adventitial angiogenesis at two weeks, both the AdsVEGFR1 and AdsVEGFR2 treated animals showed a reduction in ISR six weeks after the treatment. The reduced angiogenesis seen at the two-week time point likely contributes to the reduced ISR four weeks later.
In fact it has been shown that the adventitial tissue surrounding arterial stents is hypoxic in nature and this hypoxia leads to the growth of adventitial vessels, this adventitial angiogenesis is reduced by AdsVEGFR1 and AdsVEGFR2 therapy in this study [27] . Interestingly, a similar degree of reduction in ISR was seen with AdsVEGFR1 although its effects on vasa-vasorum at d14 were more limited compared to AdsVEGFR2 therapy. The results are in line with previous findings ACCEPTED MANUSCRIPT
showing increased neointima formation in rabbit carotid arteries following adventitial VEGF gene transfers [28] . Similar to the loss of the anti-angiogenic effect, no effects on ISR were observed at the extended follow-up of 90 days. The transient therapeutic effects suggests that an alternative vector system or other delivery method should be considered in the future to accomplish more sustained reduction in ISR.
The in-stent neointima formation observed already at the two-week time-point represents more than half of the ISR seen at the extended follow-up of 90d in all treatment groups. This finding confirms that the acute phase of 1-2 weeks after the stent placement is critical for the healing process of the artery and the onset of ISR [29] . While a drug eluting stent will potentially start the release of therapeutic agent immediately after stent implantation, all gene therapy based approaches have the limitation of delayed onset of therapy as the therapeutic protein will only be produced after sufficient transduction of the transgene.
The rate of regeneration of the luminal endothelium was similar in all groups at all time points and was not influenced by the transient adventitial expression of anti-angiogenic decoy receptors.
Physiological VEGF signaling maintains endothelial homeostasis [30] and is necessary for endothelial recovery after stenting. The adventitial expression in this study seems to limit Treatment with AdsVEGFR3 led to an altered composition of the developing neointima, which was observed already at d14 (Fig 5) . AdsVEGFR3 treated arteries showed more complicated neointimal changes with higher atherosclerotic lesion scores [20, 21] . 
CONCLUSIONS
This study suggests that adventitial plaque angiogenesis plays an important role in the pathogenesis of ISR. Importantly, the abluminal delivery of anti-angiogenic agents reduced ISR but did not affect the regeneration of luminal endothelium. Conversely, periadventitial inhibition of lymphangiogenic signaling adversely influenced healing after stent implantation. Therefore, local gene therapy is a potential new way to reduce adventitial angiogenesis and ISR in patients who require angioplasty and stent placement.
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None. A C C E P T E D M A N U S C R I P T (atherosclerotic severity score [1] [2] [3] [4] [5] [6] Results of various assessments of stent histology. Injury score determined for each strut (0-3) and averaged for the stent. Statistical significance represented with *<0.05, **<0.01, ***<0.001.
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Comparisons are made to AdLacZ treated animals.
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A C C E P T E D M A N U S C R I P T CD31 and Ki-67 stainings for myocardium from samples collected at d14, d42 and d90 time-points.
Magnifications 100x.
Supplementary Figure 2.
CD31 and Ki-67 stainings for lungs from samples collected at d14, d42 and d90 time-points.
Supplementary Figure 3.
CD31 and Ki-67 stainings for kidneys from samples collected at d14, d42 and d90 time-points.
Supplementary Figure 4.
CD31 and Ki-67 stainings for liver from samples collected at d14, d42 and d90 time-points.
Supplementary Figure 5.
CD31 and Ki-67 stainings for spleen from samples collected at d14, d42 and d90 time-points.
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